etodolac has been researched along with Helicobacter Infections in 4 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some adaptation occurred in over 90% of subjects after 4 weeks dosing with an NSAID, but adaptation was less frequent in older subjects and in smokers." | 1.30 | The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs. ( Campbell, F; Lipscomb, GR; Rees, WD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Magari, H | 1 |
| Shimizu, Y | 1 |
| Inada, K | 1 |
| Enomoto, S | 1 |
| Tomeki, T | 1 |
| Yanaoka, K | 1 |
| Tamai, H | 1 |
| Arii, K | 1 |
| Nakata, H | 1 |
| Oka, M | 1 |
| Utsunomiya, H | 1 |
| Tsutsumi, Y | 1 |
| Tsukamoto, T | 1 |
| Tatematsu, M | 1 |
| Ichinose, M | 1 |
| Laine, L | 1 |
| Cominelli, F | 1 |
| Sloane, R | 1 |
| Casini-Raggi, V | 1 |
| Marin-Sorensen, M | 1 |
| Weinstein, WM | 1 |
| Lipscomb, GR | 1 |
| Campbell, F | 1 |
| Rees, WD | 1 |
| Xiao, F | 1 |
| Furuta, T | 1 |
| Takashima, M | 1 |
| Shirai, N | 1 |
| Hanai, H | 1 |
1 trial available for etodolac and Helicobacter Infections
| Article | Year |
|---|---|
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Gas | 1995 |
3 other studies available for etodolac and Helicobacter Infections
| Article | Year |
|---|---|
Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Etodolac; Gerbillinae; Helicob | 2005 |
The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Tole | 1997 |
Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Eto | 2001 |